To assess the cancer specificity of the replication defects caused by MTHFD2 inhibitors, we treated AML and nontumorigenic LCL cells with TH7299, TH9619, MTX or the ATR inhibitor VE-821. This evidence concerns the gene MTHFD2 and acute myeloid leukemia.